Triptorelin pamoate

Phase 3Small molecule

Triptorelin pamoate is one of 112 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaCompleted

Central Precocious PubertyActive, not recruiting

Precocious PubertyActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Prostate AdenocarcinomaPreclinical

Completed

Central Precocious PubertyPhase 3

Active, not recruiting

Precocious PubertyPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Prostate CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Triptorelin pamoate

Ipsen

Phase 3

1 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Zinecard

CChildren's Oncology Group

Preclinical

2 4

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—5

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 6

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 7

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 8

Lipegfilgrastim

Merck & Co.

Preclinical

1 9

Promestriene

UUniversity of Sao Paulo General Hospital

Preclinical

1 10

Escitalopram Oxalate

TTorrent Pharmaceuticals Limited

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Recruiting

Adolescent

NCT06513962

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Completed· Ipsen logo

Ipsen·Phase 3·NCT01715129·126 enrolled

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

Terminated·UUniversity of California, San Francisco·Phase 2·NCT02168062·57 enrolled

Central precocious puberty2 trials

Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.

Completed· Ipsen logo

Ipsen·Phase 3·NCT04736602·32 enrolled

A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

Completed· Ipsen logo

Ipsen·Phase 3·NCT05029622·66 enrolled

Randomized1 trial

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Completed·WWatson Pharmaceuticals·Phase 4·NCT01161563·118 enrolled

Lupus1 trial

Triptorelin for Ovary Protection in Childhood Onset Lupus

Completed·—·Phase 2·NCT00124514·31 enrolled

Precocious Puberty1 trial

Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty

Completed· Ipsen logo

Ipsen·Phase 3·NCT00564850·37 enrolled

5 more indications

Adolescent1 trial

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Recruiting·CChildren's Oncology Group·Phase 3·NCT06513962·60 enrolled

Biochemical Recurrence1 trial

Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

Unknown status·CCancer Research Antwerp·Phase 2·NCT03899077·202 enrolled

Breast Cancer1 trial

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

Terminated·UUniversity of Washington·Phase 2·NCT00194792·28 enrolled

Prostate Adenocarcinoma1 trial

A Phase I/II Study of High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer

Completed·SStanford University·Preclinical·NCT02346253·146 enrolled

Unspecified1 trial

Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg

Completed· Ipsen logo

Ipsen·Phase 2·NCT01257425·109 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Triptorelin pamoate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triptorelin pamoate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triptorelin pamoate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Ipsen

Triptorelin pamoate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Prostate Cancer2 trials

Central precocious puberty2 trials

Randomized1 trial

Lupus1 trial

Precocious Puberty1 trial

Adolescent1 trial

Biochemical Recurrence1 trial

Breast Cancer1 trial

Prostate Adenocarcinoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News